Page last updated: 2024-10-31

entinostat and Peritoneal Carcinomatosis

entinostat has been researched along with Peritoneal Carcinomatosis in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Gupta, VG1
Hirst, J1
Petersen, S1
Roby, KF1
Kusch, M1
Zhou, H1
Clive, ML1
Jewell, A1
Pathak, HB1
Godwin, AK1
Wilson, AJ1
Crispens, MA1
Cybulla, E1
Vindigni, A1
Fuh, KC1
Khabele, D1

Other Studies

1 other study available for entinostat and Peritoneal Carcinomatosis

ArticleYear
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gynecologic oncology, 2021, Volume: 162, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; BRCA1 Protein; Carcinoma, Ovari

2021